PTC Therapeutics, Inc. $PTCT Shares Bought by Sei Investments Co.

Sei Investments Co. lifted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 41.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 130,204 shares of the biopharmaceutical company’s stock after acquiring an additional 38,115 shares during the quarter. Sei Investments Co.’s holdings in PTC Therapeutics were worth $8,871,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Teachers Retirement System of The State of Kentucky raised its holdings in PTC Therapeutics by 86.9% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 40,858 shares of the biopharmaceutical company’s stock worth $3,103,000 after purchasing an additional 19,000 shares during the last quarter. Thrivent Financial for Lutherans purchased a new stake in PTC Therapeutics during the fourth quarter worth $4,191,000. Ritholtz Wealth Management acquired a new stake in PTC Therapeutics in the fourth quarter valued at $1,863,000. Royce & Associates LP grew its holdings in PTC Therapeutics by 146.5% in the fourth quarter. Royce & Associates LP now owns 80,794 shares of the biopharmaceutical company’s stock valued at $6,137,000 after purchasing an additional 48,015 shares during the last quarter. Finally, M&T Bank Corp purchased a new position in shares of PTC Therapeutics in the fourth quarter valued at $1,859,000.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
• Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

PTC Therapeutics Trading Down 9.9%

NASDAQ:PTCT opened at $68.01 on Friday. PTC Therapeutics, Inc. has a 12-month low of $43.17 and a 12-month high of $90.87. The firm has a market cap of $5.64 billion, a price-to-earnings ratio of -117.26, a price-to-earnings-growth ratio of 5.92 and a beta of 0.53. The company’s 50-day moving average is $77.57 and its two-hundred day moving average is $72.74.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.68. The business had revenue of $360.52 million during the quarter, compared to the consensus estimate of $298.63 million. PTC Therapeutics had a negative net margin of 3.80% and a negative return on equity of 362.45%. The company’s quarterly revenue was up 101.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.83) earnings per share. On average, equities research analysts forecast that PTC Therapeutics, Inc. will post 0.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mary L. Smith sold 15,834 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $90.00, for a total transaction of $1,425,060.00. Following the sale, the director owned 21,813 shares in the company, valued at $1,963,170. This trade represents a 42.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Neil Gregory Almstead sold 2,464 shares of PTC Therapeutics stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $90.25, for a total value of $222,376.00. Following the completion of the sale, the insider directly owned 60,299 shares of the company’s stock, valued at approximately $5,441,984.75. This represents a 3.93% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 198,662 shares of company stock valued at $16,347,994. Company insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on PTCT. Citigroup raised PTC Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $75.00 to $108.00 in a research note on Tuesday, June 9th. Morgan Stanley raised their target price on shares of PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a report on Friday. Jefferies Financial Group upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the stock from $76.00 to $85.00 in a research report on Wednesday, May 27th. TD Cowen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the company from $75.00 to $90.00 in a report on Friday, May 8th. Finally, Zacks Research upgraded shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.